Please login to the form below

Not currently logged in
Email:
Password:

cost-effectiveness

This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

England's cost effectiveness watchdog says the company has supplied insufficient evidence to demonstrate that it is more effective than botulinum toxin type A, and that the data presented doesn’t ... Ahmad adds: “NICE does not consider impact of

Latest news

  • AstraZeneca wins NICE backing for asthma injection AstraZeneca wins NICE backing for asthma injection

    The recommendation from England's cost effectiveness watchdog gives AZ's injection a toe-hold in the market, where GSK's Nucala and Teva's Cinqaero are already NICE-approved. . ... The UK’s cost effectiveness watchdog said in an earlier appraisal

  • NICE appraisal fees to be introduced despite opposition NICE appraisal fees to be introduced despite opposition

    Concessions made for small companies. England’s cost effectiveness watchdog NICE is to start charging pharmaceutical companies for appraisals of their drugs from April 2019, despite considerable resistance from the industry ... whole, and adjusted to

  • Beneluxa: the future of European market access? Beneluxa: the future of European market access?

    the key was that Netherlands and Belgium showed flexibility in their cost- effectiveness assessment. ... In this case one institute undertakes the clinical assessment and the other oversees the cost- effectiveness assessment for both countries.

  • NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

    But it is only available via the CDF for now. England's cost effectiveness watchdog NICE has recommended BMS' Opdivo  as an adjuvant treatment for skin cancer, reversing its initial decision ... This means that the clinical and cost effectiveness of

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    England's cost effectiveness watchdog NICE has given the go-ahead for the drug to be used in this setting, opening up the drug to more than 3, 000 non-small ... NICE says Keytruda (pembrolizumab) “has the potential to be cost-effective, and was likely

More from news
Approximately 3 fully matching, plus 502 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics